Come up with a name for your new list and we'll add to it:
Nivalis Therapeutics raised a round of funding on July 21, 2017. Investors include
Alpine Immune Sciences.
Nivalis Therapeutics, formerly N30Pharma, is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule wit…